Previous 10 |
This article was first released to subscribers 1 month ago. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence and investigation. Previous editions of the Report can be searched using the ke...
Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence and investigation. Previous editions of the report can be searched using the keyword "cefrep". A database of CEFs was obtained from CEFConne...
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Cornerstone Strategic Value Fund, Inc. (“CLM”) and Cornerstone Total Return Fund, Inc. (“CRF”) (individually the “Fund” or, collectively, the “Funds”) have each filed copies of their annual ...
Cornerstone Strategic Value Fund (NYSEMKT: CLM ) declares $0.2053/share monthly dividend , in line with previous. More news on: Cornerstone Strategic Value Fund, Dividend News, , Read more ...
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Cornerstone Strategic Value Fund, Inc. (NYSE American: CLM) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF), (individually the “Fund” or, collectively, the “Funds”), each a closed-end management investment ...
This article was first released to subscribers 1 month ago. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence and investigation. Previous editions of the Report can be searched using the ke...
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...